H
HitGen
HitGen is a platform company based on its leading DNA-encoded library (DELs) technology for innovative drug discovery research
About HitGen
HitGen is a biotechnology company specializing in innovative drug discovery using DNA-encoded library (DEL) technology. The company operates in the pharmaceutical and biotechnology markets, focusing on creating novel molecules for hit identification and lead generation. HitGen's primary clients include pharmaceutical companies and research institutions seeking to develop new treatments for diseases such as oncology, cardiovascular diseases (CVD), inflammation, respiratory conditions, metabolism disorders, and ophthalmology. The business model revolves around collaborative projects, licensing agreements, and proprietary research initiatives. HitGen generates revenue through partnerships, licensing fees, and milestone payments from successful drug development projects. The company has a robust pipeline with over 20 internal projects, including several in advanced stages of development.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
News
Open roles
HitGen in the Chengdu ecosystem
The HitGen office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- LCLeadyond capital
CDH Investments
Series B and later2 investors entered at this stage
- LCLeadyond capital
CDH Investments
Source: Dealroom Talent Intelligence.
See HitGen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

